Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Application Health and Innovation Thought Leader Delegation till Singapore, 19-21 November 2024

Reference number
Coordinator NEOGAP Therapeutics AB
Funding from Vinnova SEK 24 549
Project duration November 2024 - November 2024
Status Completed
Venture Global cooperation 2024

Important results from the project

Vi satte inga mål och ansökningstuden var formidabelt kort

Expected long term effects

It is to early to speculate about the far-reaching effects. It is clear that the product has an enormous potential to become the dominant player in the field of solid cancer.

Approach and implementation

We carried out the project, the trip to Singapore and took the opportunity to establish an interesting collaboration

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 17 January 2025

Reference number 2024-03715